AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Antibodies, MonoclonalTumor Necrosis Factor-alphaReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIInterleukin-1CytokinesLipopolysaccharidesInterleukin-6Cells, CulturedNecrosisNF-kappa BRNA, MessengerInterferon-gammaMacrophagesCell LineMice, Inbred C57BLLymphotoxin-alphaRecombinant ProteinsMonocytesMice, Inbred BALB CSignal TransductionApoptosisInflammationGene Expression RegulationTumor Necrosis FactorsMolecular Sequence DataArthritis, RheumatoidGene ExpressionTransforming Growth Factor alphaEnzyme-Linked Immunosorbent AssayInterleukin-10Antigens, CDInterleukin-8Dose-Response Relationship, DrugBase SequenceAntirheumatic AgentsMice, KnockoutTumor Necrosis Factor Decoy ReceptorsTime FactorsDisease Models, AnimalMacrophage ActivationReverse Transcriptase Polymerase Chain ReactionSynovial MembraneCell Line, TumorTumor Cells, CulturedLeukocytes, MononuclearUp-RegulationMembrane GlycoproteinsTransfectionFlow CytometryInterleukin-1betaT-LymphocytesBlotting, WesternImmunohistochemistryNeutrophilsImmunoglobulin GCell DivisionInflammation MediatorsEndotoxinsCell SurvivalDrug SynergismFibroblastsMacrophages, PeritonealI-kappa B ProteinsDown-RegulationAnti-Inflammatory AgentsEnzyme ActivationTranscription, GeneticPentoxifyllinePromoter Regions, GeneticMice, Inbred C3HKineticsLiverEndothelium, VascularAmino Acid SequenceReceptors, Cell SurfaceInterleukin-12I-kappa B KinaseIntercellular Adhesion Molecule-1TNF Receptor-Associated Factor 2Nitric OxideAntibodiesTumor Markers, BiologicalTranscription Factor RelAGranulocyte-Macrophage Colony-Stimulating FactorPhosphorylationLymphocyte ActivationSpleenLungPolymerase Chain ReactionAntigens, CD14Tumor Necrosis Factor Receptor-Associated Peptides and ProteinsProtein BindingInterleukinsTNF-Related Apoptosis-Inducing LigandShock, SepticDendritic CellsDNA PrimersCell Differentiation
AntibodiesInfliximabBinding to a spChimericAnti-tumourCytokinesFully Human MonoclonalAntibody that blocksAdalimumabTherapeuticReactsMacrophage-derivedInflammationCloneCrohn'sTNFalphaCertolizumab PegolArthritisTNFaInhibitorEfficacyAntagonistTherapyRecombinantCytokineCytotoxicReceptorLesionsDilutionTreatmentClinicalPatientsInflammatoryMembraneChronicBindMouseTranscription factorCells
Antibodies6
Infliximab10
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. (nih.gov)
  • We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. (nih.gov)
  • 32 were treated with a single infusion of the anti-TNF monoclonal antibody Infliximab at a dose of 5mg/kg body weight. (qxmd.com)
  • Infliximab is a chimeric monoclonal antibody that specifically binds both soluble and membrane bound TNFα. (bmj.com)
  • Recently biological blockade with the tumour necrosis factor alpha (TNFα) antagonists infliximab and etanercept has been shown to be effective in the treatment of SpA. (bmj.com)
  • 1 Historically the therapeutic options in SpA have been limited, but recent studies have shown that biological blockade with the tumour necrosis factor α (TNFα) antagonists infliximab and etanercept is efficacious in ankylosing spondylitis 2, 3 and psoriatic arthritis. (bmj.com)
  • We investigated whether infliximab, an anti-TNF-alpha therapy, may modify the lipid profile. (researchgate.net)
  • Patients treated with infliximab-a monoclonal antibody against tumor necrosis factor-alpha-had a significant improvement at week eight. (medicaleconomics.com)
  • Infliximab, an antibody to human tumor necrosis factor alpha, has proved successful in the treatment of severe refractory disease and generally causes only mild side effects. (aafp.org)
  • The pharmacokinetics of infliximab (IFX), an anti-TNF-α monoclonal antibody, is modified during methotrexate (MTX) coadministration in rheumatoid arthritis[1]. (page-meeting.org)
Binding to a sp1
  • Golimumab acts by binding to a specific protein in the body called tumour necrosis factor (TNF) alpha. (mydr.com.au)
Chimeric1
  • To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA). (nih.gov)
Anti-tumour1
  • Randomised controlled trials have shown that treatment with anti-tumour necrosis factor (anti-TNF) agents is effective in refractory rheumatoid arthritis (RA). (bmj.com)
Cytokines2
  • Given the importance of CD4 + Th cells in the disease process, this review will focus on how Th cells differentiate in the inflamed intestinal tract during IBD and how the Th lineage-specific cytokines and transcription factors (TFs) contribute to disease. (frontiersin.org)
  • Interleukin (IL)-12 and IL-23, cytokines induced during early stages of IBD, play important roles in differentiation of interferon (IFN)-γ/tumor necrosis factor (TNF)-producing Th1 cells as well as IL-17-producing Th17 cells. (frontiersin.org)
Fully Human Monoclonal1
  • Dupilumab is a fully human monoclonal antibody that blocks a shared receptor component for interleukin-4 and interleukin-13, which are the key drivers for type 2 inflammation with EoE. (medscape.com)
Antibody that blocks1
  • My rheumatologist prescribed halobetasol propionate topical cream for the blisters and initiated the insurance preauthorization process for guselkumab, a monoclonal antibody that blocks interleukin-23. (creakyjoints.org)
Adalimumab2
  • Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). (globenewswire.com)
  • Adalimumab is a monoclonal antibody that neutralizes the activity of tumor necrosis factor alpha (TNF-α), a protein that plays a central role in inflammatory reactions in patients with autoimmune diseases. (eisai.com)
Therapeutic3
  • These preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease. (nih.gov)
  • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. (ox.ac.uk)
  • Matsuoka, K & Kanai, T 2013, ' Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease ', Digestion , vol. 88, no. 1, pp. 17-19. (elsevierpure.com)
Reacts3
  • Description: The MAR-1 monoclonal antibody reacts with the Fc epsilon Receptor I alpha subunit, an IgE-binding subunit lacking signal-transducing ability. (thermofisher.com)
  • The monoclonal antibody 52B83 reacts with tumor necrosis factor alpha (TNF-alpha). (hycultbiotech.com)
  • Reacts with soluble (17kD) and membrane (26kD) human TNF-alpha. (lsbio.com)
Macrophage-derived1
Inflammation4
  • Although the cause of AS is unknown, it is believed that immunological factors and other factors such as infection with specific bacteria play important roles in causing an immune disorder which induces inflammation of the ligaments and tendons where they attach to bone and eventually rigidity of the spine and other joints. (eisai.com)
  • About SIMPONI ® (golimumab) SIMPONI is a human monoclonal antibody that targets and neutralises excess tumor necrosis factor (TNF)-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation and damage to bones, cartilage and tissue. (jnj.com)
  • However, if they are treated with anti-Tumor Necrosis Factor alpha (anti-TNFα) therapy, a monoclonal antibody that is commonly used to control inflammation in IBD patients, then their risk of developing Parkinson's disease goes down significantly, and becomes even lower than that in the general population. (mountsinai.org)
  • It works by inhibiting tumour necrosis factor alpha (TNF-alpha), a naturally occurring protein that promotes inflammation. (hospitalpharmacyeurope.com)
Clone1
  • Anti HTLV I Mouse Monoclonal Clone 68/4. (caslab.com)
Crohn's2
  • 3 Environmental factors must play a role in the development of Crohn's disease, because while the disease is uncommon in African blacks, U.S. blacks have an incidence similar to that of whites. (aafp.org)
  • While etiologic evidence suggests a complex interplay between many factors, pathophysiologically, Crohn's disease involves an immune system dysfunction. (aafp.org)
TNFalpha2
  • There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. (nih.gov)
  • Tumor necrosis factor-alpha (TNFalpha) has been demonstrated to play an important role in its pathophysiology. (qxmd.com)
Certolizumab Pegol1
  • Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. (wikipedia.org)
Arthritis3
  • A handout on this topic is available at http://familydoctor.org/familydoctor/en/diseases-conditions/rheumatoid-arthritis.html . (aafp.org)
  • In a patient with inflammatory arthritis, the presence of a rheumatoid factor and/or anti-citrullinated protein antibody, elevated C-reactive protein level, or elevated erythrocyte sedimentation rate is consistent with a diagnosis of rheumatoid arthritis. (aafp.org)
  • The pro-inflammatory properties of- TNF-alpha play a central role in several auto-immune diseases such as rheumatoid arthritis and inhibition by neutralizing molecules have been shown to be beneficial in patients. (hycultbiotech.com)
TNFa1
Inhibitor2
  • More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. (wikipedia.org)
  • A molecular signature response classifier (MSRC) that predicts which patients with RA are unlikely to respond to tumor necrosis factor-α inhibitor (TNFi) therapy would have wide clinical utility. (springer.com)
Efficacy1
  • Strategies that selectively target tumour necrosis factor α (TNFα) have shown efficacy when tested in patients with considerable disease activity despite treatment with disease modifying antirheumatic drugs (DMARDs). (bmj.com)
Antagonist1
  • Three patients underwent a medical history for TB risk factors before beginning therapy with a TNF-α antagonist. (cdc.gov)
Therapy4
  • Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. (qxmd.com)
  • Salvage therapy for patients with resistant disease or relapse includes reuse or alternative use of front-line agent, combination therapy, thalidomide (with or without steroids), autologous transplantation, and monoclonal antibody (alemtuzumab). (medscape.com)
  • Various dermatological conditions have been reported during tumor necrosis factor (TNF)-α-blocking therapy, but until now no prospective studies have been focused on this aspect. (biomedcentral.com)
  • 1) These costs savings can be utilised to treat more patients with monoclonal antibody therapy, to treat patients earlier in the disease pathway or to reallocate resources. (hospitalpharmacyeurope.com)
Recombinant3
  • Golimumab is a human monoclonal antibody that is produced by recombinant technology. (mydr.com.au)
  • Recognizes human native and recombinant TNF-alpha. (lsbio.com)
  • Western Blot: TNF-alpha Antibody [NBP1-19532] - Recombinant human TNF alpha (10 ng) was separated on a 12% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. (novusbio.com)
Cytokine2
  • Tumor necrosis factor-alpha (TNF-alpha), a pivotal pro-inflammatory cytokine in RA may be involved in the development of the disturbed lipid metabolism. (researchgate.net)
  • TNF-alpha was originally described as a highly cytotoxic cytokine for tumor cells, it causes tumor necrosis in vivo and shows cytolytic activity against tumor cells in vitro. (hycultbiotech.com)
Cytotoxic1
  • These cells primarily produce interferon (IFN)-γ and tumor necrosis factor (TNF) that, respectively, activate macrophages and direct cytotoxic CD8 + T cell responses, that in turn promote elimination of intracellular pathogens such as viruses and bacteria ( 8 ). (frontiersin.org)
Receptor4
  • STAT4 also signals activation of the TF T-bet, a lineage-defining factor for Th1 differentiation, which upregulates the IL-12 receptor, IFN-γ expression, and causes further expansion of Th1 cells (Figure 1 ) ( 12 ). (frontiersin.org)
  • FceR1 (Fc epsilonR1 alpha) is a subunit of the high affinity receptor of IgE. (thermofisher.com)
  • TNF-alpha is a homotrimeric 17 kDa protein, that interacts with either one of the two types of TNF-receptors, termed I and II, leading to receptor cross-linking and signal transduction. (hycultbiotech.com)
  • Does not cross-react with TNF-beta, lymphotoxin and receptor bound TNF-alpha. (lsbio.com)
Lesions2
  • Periapical lesions are diseases resulting from contamination and necrosis of dental pulp and the progression of this infection toward the periapical tissues. (bvsalud.org)
  • Technological advances in microbiological culture and identification have shown that anaerobic microorganisms, especially Gram-negative, are predominate in root canals of teeth with pulp necrosis and chronic periapical lesions. (bvsalud.org)
Dilution1
  • Immunohistochemistry-Paraffin: TNF-alpha Antibody [NBP1-19532] - Analysis of a FFPE tissue section of mouse intestine using TNF-alpha antibody (NBP1-19532) at 1:300 dilution. (novusbio.com)
Treatment2
  • Treatment with anti-TNF alpha was safe and well tolerated and resulted in significant clinical and laboratory improvements. (nih.gov)
  • Remsima is the first authorised biosimilar monoclonal antibody and is licenced by the European Medicines Agency (EMA) for the treatment of chronic, debilitating and often painful inflammatory autoimmune conditions that affect over seven million people across Europe. (hospitalpharmacyeurope.com)
Clinical1
  • Initial management consisted of en una paciente con topical corticosteroids and oral antihistamines with little clinical response. (bvsalud.org)
Patients4
  • Twenty patients with active RA were treated with 20 mg/kg of anti-TNF alpha in an open phase I/II trial lasting 8 weeks. (nih.gov)
  • Eleven of the patients had at least one risk factor for LTBI (e.g., born in countries where TB is prevalent or contact with a person with TB disease). (cdc.gov)
  • Patients with AS are typically negative for rheumatoid factor. (eisai.com)
  • Ils ont été répartis en deux groupes : 12 patients souffrant d'une thrombocytopénie à médiation immunitaire (groupe 1) et 12 patients atteints d'une thrombocytopénie à médiation non immunitaire (groupe 2). (who.int)
Inflammatory2
  • Critical factors in the differentiation of effector Th cells during inflammatory bowel disease (IBD). (frontiersin.org)
  • Furthermore,- TNF-alpha is found to be a central mediator in many inflammatory and immunological processes. (hycultbiotech.com)
Membrane1
  • Gram-negative bacteria not only have different factors of virulence and generate products and sub-products that are toxic to apical and periapical tissues, but also contain endotoxin in the outer membrane of their cell wall. (bvsalud.org)
Chronic1
  • It is currently known that the infection in deciduous and permanent teeth with pulp necrosis and chronic periapical lesion is polymicrobial, with a predominance of strict anaerobic microorganisms, particularly Gram-negative 1,3-5 . (bvsalud.org)
Bind1
  • Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone. (medicaldialogues.in)
Mouse2
  • Monoclonal antibody to mouse tumor necrosis factor alpha (TNF-α): Hamster IgG. (aniara.com)
  • TNF Alpha antibody LS-B2123 is an unconjugated mouse monoclonal antibody to TNF Alpha from human. (lsbio.com)
Transcription factor1
  • WWP2 interacts with transcription factor IRF7, promoting its non-degradative mono-ubiquitination, nuclear translocation and transcriptional activity, leading to upregulation of Ccl5 at transcriptional level. (nature.com)
Cells1